Ablynx extends research collaboration with Boehringer Ingelheim
In January 2007 Boehringer Ingelheim and Ablynx had entered into a $265 million worldwide research and licensing agreement to discover and develop new therapies for Alzheimer’s disease using
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.